The Aroon Indicator for ENTA entered a downward trend on October 06, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 330 similar instances where the Aroon Indicator formed such a pattern. In 298 of the 330 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ENTA as a result. In 63 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for ENTA turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 46 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
ENTA moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ENTA crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENTA advanced for three days, in 219 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
ENTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. ENTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.635) is normal, around the industry mean (26.782). ENTA's P/E Ratio (594.960) is considerably higher than the industry average of (43.395). Projected Growth (PEG Ratio) (0.550) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (5.285) is also within normal values, averaging (437.542).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IMNM declined for three days, in 261 of 303 cases, the price declined further within the following month. The odds of a continued downward trend are 86%.
IMNM moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IMNM crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for IMNM entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNM advanced for three days, in 238 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
IMNM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.690) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. IMNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ENTA | IMNM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 78 | 76 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 63 | 65 | |
P/E GROWTH RATING 1..100 | 1 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IMNM's Valuation (65) in the null industry is somewhat better than the same rating for ENTA (99) in the Biotechnology industry. This means that IMNM’s stock grew somewhat faster than ENTA’s over the last 12 months.
IMNM's Profit vs Risk Rating (100) in the null industry is in the same range as ENTA (100) in the Biotechnology industry. This means that IMNM’s stock grew similarly to ENTA’s over the last 12 months.
IMNM's SMR Rating (98) in the null industry is in the same range as ENTA (98) in the Biotechnology industry. This means that IMNM’s stock grew similarly to ENTA’s over the last 12 months.
ENTA's Price Growth Rating (63) in the Biotechnology industry is in the same range as IMNM (65) in the null industry. This means that ENTA’s stock grew similarly to IMNM’s over the last 12 months.
ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for IMNM (100) in the null industry. This means that ENTA’s stock grew significantly faster than IMNM’s over the last 12 months.
| ENTA | IMNM | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 70% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 80% | N/A |
| MACD ODDS (%) | 1 day ago 85% | N/A |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 84% |
| Advances ODDS (%) | 15 days ago 79% | 6 days ago 83% |
| Declines ODDS (%) | 1 day ago 84% | 1 day ago 86% |
| BollingerBands ODDS (%) | 1 day ago 57% | 1 day ago 87% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ENTA’s FA Score shows that 1 FA rating(s) are green while IMNM’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ENTA’s TA Score shows that 3 TA indicator(s) are bullish while IMNM’s TA Score has 4 bullish TA indicator(s).
ENTA (@Biotechnology) experienced а -9.62% price change this week, while IMNM (@Biotechnology) price change was -9.92% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.52%. For the same industry, the average monthly price growth was -19.04%, and the average quarterly price growth was -19.99%.
ENTA is expected to report earnings on Nov 16, 2026.
IMNM is expected to report earnings on Nov 16, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CORD | 4.62 | 1.08 | +30.51% |
| T-REX 2X Inverse CRWV Daily Target ETF (CORD) | |||
| SCO | 17.44 | 0.01 | +0.06% |
| ProShares UltraShort Bloomberg Crude Oil (SCO) | |||
| IWD | 254.20 | -0.33 | -0.13% |
| iShares Russell 1000 Value ETF (IWD) | |||
| HSCZ | 43.10 | -0.24 | -0.56% |
| iShares Currency Hedged MSCI EAFE Small-Cap ETF (HSCZ) | |||
| LABX | 10.40 | -1.81 | -14.82% |
| Tradr 2X Long ALAB Daily ETF (LABX) | |||
A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with XNCR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then XNCR could also see price increases.
| Ticker / NAME | Correlation To ENTA | 1D Price Change % | ||
|---|---|---|---|---|
| ENTA | 100% | -2.95% | ||
| XNCR - ENTA | 44% Loosely correlated | -0.55% | ||
| IMNM - ENTA | 44% Loosely correlated | -2.16% | ||
| VIR - ENTA | 43% Loosely correlated | -1.89% | ||
| ZYME - ENTA | 41% Loosely correlated | -1.20% | ||
| DMAC - ENTA | 40% Loosely correlated | -2.05% | ||
More | ||||
A.I.dvisor indicates that over the last year, IMNM has been loosely correlated with KYTX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNM jumps, then KYTX could also see price increases.
| Ticker / NAME | Correlation To IMNM | 1D Price Change % | ||
|---|---|---|---|---|
| IMNM | 100% | -2.16% | ||
| KYTX - IMNM | 59% Loosely correlated | -1.47% | ||
| SLDB - IMNM | 53% Loosely correlated | -6.10% | ||
| EDIT - IMNM | 52% Loosely correlated | -7.16% | ||
| SANA - IMNM | 49% Loosely correlated | -3.32% | ||
| MGTX - IMNM | 48% Loosely correlated | -5.33% | ||
More | ||||